Sensory Disorders – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Sensory Disorders – Drugs In Development, 2024 report and make more profitable business decisions.
Sensory Disorders or sensory processing disorders (SPD) is a neurological condition in children that affects the sensory stimuli of brain. It is also known as sensory integration dysfunction causing an increased or decreased sensitivity to light, smell, taste, sound, and touch. It is divided into 8 different types: proprioception, vestibular, interoception, and five senses. Hyposensitivity and hypersensitivity are observed in children. As a result, children shows behavioral problems, attention deficient, low pain threshold, difficulty in controlling emotions etc. ASD, Schizophrenia, brain injury, sleep disorders, developmental disorders are common conditions associated with this. There is no standard therapy for this condition hence cognitive supportive therapy provided.
The Sensory Disorders drugs in development market research report provide comprehensive information on the therapeutics under development for Sensory Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sensory Disorders and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Sensory Disorders | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 18 molecules, with 12 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Sensory Disorders therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Sensory Disorders pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Sensory Disorders treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Caventure Drug Discovery IncCharleston Laboratories Inc
Cyrano Therapeutics Inc
Delta 4 GmbH
EG 427
Exodos Life Sciences Limited Partnership
Fujian Normal University
Halia Therapeutics Inc
Johns Hopkins University
MD Healthcare Inc
Northwest University
China
Novartis AG
Ractigen Therapeutics Inc
SATT Conectus Alsace SAS
Sichuan Haisco Pharmaceutical Co Ltd
Tulane University
University of California San Diego
University of Miami Miller School of Medicine
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Sensory Disorders reports